Advertisement

Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study

  • Naoto OkadaEmail author
  • Masayuki Chuma
  • Momoyo Azuma
  • Shingen Nakamura
  • Hirokazu Miki
  • Hirofumi Hamano
  • Mitsuhiro Goda
  • Kenshi Takechi
  • Yoshito Zamami
  • Masahiro Abe
  • Keisuke Ishizawa
Pharmacokinetics and Disposition

Abstract

Purpose

Appropriate use of vancomycin (VCM) is important in preventing acute kidney injury (AKI). Because of the high frequency of VCM use for febrile neutropenia and concomitant use of other nephrotoxic drugs, haematologic patients have a different nephrotoxic background compared with patients with other diseases. Therefore, it is unclear whether the risk factors of VCM-induced AKI identified in other patient groups are also applicable to haematologic patients. Herein, we performed a single-centre retrospective analysis to identify the factors associated with VCM-induced AKI in haematologic patients.

Methods

We retrospectively analysed 150 haematologic patients to whom VCM was administered between April 2010 and March 2018 at Tokushima University Hospital. VCM-induced AKI was defined according to Kidney Disease Improving Global Outcomes (KDIGO) criteria. Multivariate logistic regression analyses were performed to identify risk factors for VCM-induced AKI.

Results

Seventeen patients had VCM-induced AKI. Multivariate analysis revealed that the risk factors of VCM-induced AKI were an initial VCM trough concentration of > 15 mg/L and concomitant use of tazobactam/piperacillin (TAZ/PIPC) and liposomal amphotericin B (L-AMB). Patients with an initial VCM trough concentration of < 10 mg/L showed significantly lower efficacy in febrile neutropenia. Interestingly, concomitant L-AMB use increased the incidence of VCM-induced AKI in a VCM concentration–dependent manner, whereas concomitant TAZ/PIPC increased the incidence in a VCM concentration–independent manner.

Conclusions

The optimal initial VCM trough concentration was 10–15 mg/L in haematologic patients, considering safety and effectiveness. There were differences in the effect of VCM-induced AKI between nephrotoxic drugs.

Keywords

Vancomycin Acute kidney injury Therapeutic drug monitoring Tazobactam/piperacillin Liposomal amphotericin B 

Notes

Authors’ contribution

NO reviewed the electronic records, performed the statistical analyses, and drafted the manuscript. MC assisted with the study design and drafted the manuscript. MA, SN, and HM reviewed the electronic records. HH, MG, KT, and YZ assisted with the study design. M. Abe and KI contributed to drafting the manuscript. All authors approved the final manuscript.

Funding information

This study was supported by a grant from the Japanese Society of Nephrology and Pharmacotherapy and JSPS KAKENHI Grant Number 19K16414.

Compliance with ethical standards

The survey content and methods to protect personal information were approved by the Tokushima University Hospital Ethics Committee and were in accordance with the stipulations on the handling of patient personal information (Ethics Committee Registration Number: 3245).

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

228_2019_2756_MOESM1_ESM.docx (127 kb)
ESM 1 (DOCX 127 kb)

References

  1. 1.
    Bamgbola O (2016) Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab 7(3):136–147.  https://doi.org/10.1177/2042018816638223 CrossRefGoogle Scholar
  2. 2.
    Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A (2012) Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 68(9):1243–1255.  https://doi.org/10.1007/s00228-012-1259-9 CrossRefGoogle Scholar
  3. 3.
    Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH (2007) A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 29(6):1107–1115.  https://doi.org/10.1016/j.clinthera.2007.06.014 CrossRefGoogle Scholar
  4. 4.
    Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL (2009) Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49(4):507–514.  https://doi.org/10.1086/600884 CrossRefGoogle Scholar
  5. 5.
    van Hal SJ, Paterson DL, Lodise TP (2013) Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 57(2):734–744.  https://doi.org/10.1128/aac.01568-12 CrossRefGoogle Scholar
  6. 6.
    Balci C, Uzun O, Arici M, Hayran SA, Yuce D, Unal S (2018) Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern? Int J Antimicrob Agents 52(2):180–184.  https://doi.org/10.1016/j.ijantimicag.2018.03.024 CrossRefGoogle Scholar
  7. 7.
    Chen XY, Xu RX, Zhou X, Liu Y, Hu CY, Xie XF (2018) Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: a systematic review and meta-analysis. Int Urol Nephrol 50(11):2019–2026.  https://doi.org/10.1007/s11255-018-1870-5 CrossRefGoogle Scholar
  8. 8.
    Okada N, Fushitani S, Azuma M, Nakamura S, Nakamura T, Teraoka K, Watanabe H, Abe M, Kawazoe K, Ishizawa K (2016) Clinical evaluation of pharmacist interventions in patients treated with anti-methicillin-resistant Staphylococcus aureus agents in a hematological ward. Biol Pharm Bull 39(2):295–300.  https://doi.org/10.1248/bpb.b15-00774 CrossRefGoogle Scholar
  9. 9.
    Tamura K (2005) Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents 26 Suppl 2: S123-127; discussion S133-140:123–127.  https://doi.org/10.1016/j.ijantimicag.2005.08.001 CrossRefGoogle Scholar
  10. 10.
    Suzuki Y, Tokimatsu I, Morinaga Y, Sato Y, Takano K, Kohno K, Ogata M, Hiramatsu K, Itoh H, Kadota J (2015) A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy. Clin Chim Acta 440:183–187.  https://doi.org/10.1016/j.cca.2014.11.027 CrossRefGoogle Scholar
  11. 11.
    Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, Takakura S, Tokimatsu I, Takahashi Y, Kasahara K, Okada K, Igarashi M, Kobayashi M, Hamada Y, Kimura M, Nishi Y, Tanigawara Y, Kimura T (2013) Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother 19(3):365–380.  https://doi.org/10.1007/s10156-013-0599-4 CrossRefGoogle Scholar
  12. 12.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982–992.  https://doi.org/10.1053/j.ajkd.2008.12.034 CrossRefGoogle Scholar
  13. 13.
    Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120(4):c179–c184.  https://doi.org/10.1159/000339789 Google Scholar
  14. 14.
    Wong-Beringer A, Joo J, Tse E, Beringer P (2011) Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 37(2):95–101.  https://doi.org/10.1016/j.ijantimicag.2010.10.013 CrossRefGoogle Scholar
  15. 15.
    Kullar R, Davis SL, Levine DP, Rybak MJ (2011) Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 52(8):975–981.  https://doi.org/10.1093/cid/cir124 CrossRefGoogle Scholar
  16. 16.
    Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54(5):621–629.  https://doi.org/10.1093/cid/cir895 CrossRefGoogle Scholar
  17. 17.
    Chuma M, Makishima M, Imai T, Tochikura N, Suzuki S, Kuwana T, Sawada N, Komatsu T, Sakaue T, Kikuchi N, Yoshida Y, Kinoshita K (2018) Relationship between initial vancomycin trough levels and early-onset vancomycin-associated nephrotoxicity in critically ill patients. Ther Drug Monit 40(1):109–114.  https://doi.org/10.1097/ftd.0000000000000459 Google Scholar
  18. 18.
    Ramphal R, Bolger M, Oblon DJ, Sherertz RJ, Malone JD, Rand KH, Gilliom M, Shands JW Jr, Kramer BS (1992) Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 36(5):1062–1067.  https://doi.org/10.1128/aac.36.5.1062 CrossRefGoogle Scholar
  19. 19.
    Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ (2006) Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42(5):597–607.  https://doi.org/10.1086/500139 CrossRefGoogle Scholar
  20. 20.
    Cook KM, Gillon J, Grisso AG, Banerjee R, Jimenez-Truque N, Phillips EJ (2019) Van driest SL (2018) incidence of nephrotoxicity among pediatric patients receiving vancomycin with either piperacillin-tazobactam or cefepime: a cohort study. J Pediatr Infect Dis Soc.  https://doi.org/10.1093/jpids/piy030
  21. 21.
    Hundeshagen G, Herndon DN, Capek KD, Branski LK, Voigt CD, Killion EA, Cambiaso-Daniel J, Sljivich M, De Crescenzo A, Mlcak RP, Kinsky MP, Finnerty CC, Norbury WB (2017) Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients. Crit Care 21(1):318.  https://doi.org/10.1186/s13054-017-1899-3 CrossRefGoogle Scholar
  22. 22.
    Clemmons AB, Bech CF, Pantin J, Ahmad I (2018) Acute kidney injury in hematopoietic cell transplantation patients receiving vancomycin and piperacillin/tazobactam versus vancomycin and cefepime. Biol Blood Marrow Transpl 24(4):820–826.  https://doi.org/10.1016/j.bbmt.2017.12.799 CrossRefGoogle Scholar
  23. 23.
    Personett HA, Kayhart BM, Barreto EF, Tosh P, Dierkhising R, Mara K, Leung N (2019) Renal recovery following liposomal amphotericin B-induced nephrotoxicity. Int J Nephrol 2019(8629891):1–8.  https://doi.org/10.1155/2019/8629891 CrossRefGoogle Scholar
  24. 24.
    Stanzani M, Vianelli N, Cavo M, Maritati A, Morotti M, Lewis RE (2017) Retrospective cohort analysis of liposomal amphotericin B nephrotoxicity in patients with hematological malignancies. Antimicrob Agents Chemother 61(9).  https://doi.org/10.1128/aac.02651-16
  25. 25.
    Okada N, Azuma M, Imanishi M, Zamami Y, Kirino Y, Nakamura T, Teraoka K, Abe M, Ishizawa K (2018) Potential usefulness of early potassium supplementation for preventing severe hypokalemia induced by liposomal amphotericin B in hematologic patients: a retrospective study. Clin Ther 40(2):252–260.  https://doi.org/10.1016/j.clinthera.2017.12.006 CrossRefGoogle Scholar
  26. 26.
    Watkins RR, Deresinski S (2017) Increasing evidence of the nephrotoxicity of piperacillin/tazobactam and vancomycin combination therapy-what is the clinician to do? Clin Infect Dis 65(12):2137–2143.  https://doi.org/10.1093/cid/cix675 CrossRefGoogle Scholar
  27. 27.
    Karimzadeh I, Farsaei S, Khalili H, Dashti-Khavidaki S (2012) Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity? Expert Opin Drug Saf 11(6):969–983.  https://doi.org/10.1517/14740338.2012.721775 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Naoto Okada
    • 1
    Email author
  • Masayuki Chuma
    • 2
  • Momoyo Azuma
    • 3
  • Shingen Nakamura
    • 4
  • Hirokazu Miki
    • 5
  • Hirofumi Hamano
    • 1
  • Mitsuhiro Goda
    • 1
  • Kenshi Takechi
    • 2
  • Yoshito Zamami
    • 1
    • 6
  • Masahiro Abe
    • 4
  • Keisuke Ishizawa
    • 1
    • 6
  1. 1.Department of PharmacyTokushima University HospitalTokushimaJapan
  2. 2.Clinical Trial Center for Developmental TherapeuticsTokushima University HospitalTokushimaJapan
  3. 3.Department of Infection Control and PreventionTokushima University HospitalTokushimaJapan
  4. 4.Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical SciencesTokushima University Graduate SchoolTokushimaJapan
  5. 5.Division of Transfusion Medicine and Cell TherapyTokushima University HospitalTokushimaJapan
  6. 6.Department of Clinical Pharmacology and TherapeuticsTokushima University Graduate School of Biomedical SciencesTokushimaJapan

Personalised recommendations